



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

December 2015





© 2016 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

**BC Centre for Excellence in HIV/AIDS
Drug Treatment Program**

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.682.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

December 2015

N = 7003



Health Authority	Male	Female	All
FRASER	1304	374	1678
INTERIOR	368	95	463
NORTHERN	132	76	208
VANCOUVER COASTAL	3354	447	3801
VANCOUVER ISLAND	656	155	811
	5814	1147	6961
		Unknown/not stated:	42
		Total:	7003

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (December 2010 - December 2015)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (December 2010 - December 2015)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (December 2010 - December 2015)






1.5 BC-CfE Enrollment: New Antiretroviral Participants
(December 2010 - December 2015)






1.6 Percent Distribution of Active Participants by CD4 Count (December 2010 - December 2015)






1.7 Percent Distribution of Inactive Participants by CD4 Count (December 2010 - December 2015)





1.8 Active and Inactive Participants (December 2010 - December 2015)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (December 2010 - December 2015)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (December 2010 - December 2015)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(December 2010 - December 2015)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (December 2010 - December 2015)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(December 2010 - December 2015)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (December 2010 - December 2015)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(December 2010 - December 2015)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (December 2010 - December 2015)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(December 2010 - December 2015)






1.18 Baseline CD4 for Antiretroviral First Starts
(December 2010 - December 2015)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(December 2010 - December 2015)






1.20 Cumulative Resistance Testing Results by Resistance Category (December 2010 - December 2015)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (December 2010 - December 2015)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2015
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	24	5	0	5	5	600	5	<40	3
1988	23	7	0	7	7	540	7	<40	3
1989	23	56	2	58	52	480	56	<40	3
1990	21	64	1	65	59	500	64	<40	3
1991	22	38	3	41	37	650	41	<40	3
1992	21	69	7	76	59	610	75	<40	3
1993	20	144	16	160	143	570	153	<40	3
1994	19	99	14	113	89	550	107	<40	3
1995	19	130	24	154	126	540	144	<40	3
1996	17	373	60	433	371	580	420	<40	3
1997	15	303	40	343	304	610	330	<40	3
1998	14	219	45	264	207	540	244	<40	3
1999	14	186	40	226	192	555	219	<40	3
2000	15	137	35	172	150	550	165	<40	3
2001	14	135	35	170	138	575	164	<40	3
2002	13	142	32	174	139	570	163	<40	3
2003	12	175	34	209	177	590	195	<40	3
2004	11	178	43	221	186	560	208	<40	3
2005	10	210	51	261	211	580	241	<40	3
2006	9	218	48	266	211	530	251	<40	3
2007	8	281	56	337	282	580	322	<40	3
2008	7	322	73	395	320	637	369	<40	3
2009	6	348	79	427	358	650	406	<40	3
2010	5	321	74	395	334	655	376	<40	3
2011	4	366	74	440	366	645	407	<40	3
2012	4	310	69	379	318	700	360	<40	3
2013	2	306	74	380	300	620	356	<40	3
2014	2	322	61	383	316	685	369	<40	3
2015	1	368	59	427	378	540	420	<40	3
Total:		5832	1149	6981					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	781	2429	<40	2151	560
FEB-2014	6570	780	1895	<40	1656	550
MAR-2014	6598	785	2156	<40	1927	550
APR-2014	6611	786	2126	<40	1874	560
MAY-2014	6677	768	2120	<40	1887	560
JUN-2014	6644	782	1994	<40	1768	550
JUL-2014	6682	778	2179	<40	1930	550
AUG-2014	6702	773	2026	<40	1806	570
SEP-2014	6730	769	2284	<40	2005	550
OCT-2014	6760	760	2250	<40	1958	570
NOV-2014	6758	756	1920	<40	1706	580
DEC-2014	6769	765	1896	<40	1689	580
JAN-2015	6743	760	2430	<40	2113	580
FEB-2015	6792	753	1978	<40	1729	570
MAR-2015	6837	747	2173	<40	1897	570
APR-2015	6850	739	2149	<40	1907	580
MAY-2015	6890	739	2032	<40	1786	560
JUN-2015	6906	739	2256	<40	1963	580
JUL-2015	6932	738	2039	<40	1793	580
AUG-2015	6930	749	2076	<40	1771	580
SEP-2015	6936	745	2269	<40	1949	580
OCT-2015	6970	738	2108	<40	1777	590
NOV-2015	7025	721	2066	<40	1740	580
DEC-2015	7003	723	2016	<40	1687	610

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1409	2265	100	6683	76	285
FEB-2014	1430	2180	73	496	67	490
MAR-2014	1432	2174	114	3726	99	340
APR-2014	1442	2150	112	128	90	400
MAY-2014	1413	2311	90	617	76	350
JUN-2014	1466	2055	96	423	82	380
JUL-2014	1458	2112	95	982	76	355
AUG-2014	1451	2161	87	208	72	365
SEP-2014	1450	2183	103	866	89	390
OCT-2014	1438	2255	84	257	62	395
NOV-2014	1451	2234	74	3945	64	400
DEC-2014	1473	2173	93	557	72	340
JAN-2015	1511	2045	105	1364	85	310
FEB-2015	1494	2120	101	78	86	380
MAR-2015	1468	2278	101	56	92	405
APR-2015	1473	2263	83	2239	68	465
MAY-2015	1455	2375	73	148	60	430
JUN-2015	1471	2305	94	106	88	430
JUL-2015	1464	2362	70	768	53	380
AUG-2015	1475	2325	81	2496	73	440
SEP-2015	1495	2284	87	128	75	345
OCT-2015	1477	2383	73	<40	57	380
NOV-2015	1450	2543	84	302	69	480
DEC-2015	1490	2347	78	314	56	360

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1409	2	30	144	136	35	11493
FEB-2014	6548	1430	9	40	139	159	9	11537
MAR-2014	6573	1432	9	36	151	146	25	11581
APR-2014	6587	1442	5	27	159	161	14	11617
MAY-2014	6646	1413	14	38	191	152	59	11667
JUN-2014	6618	1466	7	24	142	183	-28	11705
JUL-2014	6659	1458	8	34	176	159	41	11749
AUG-2014	6682	1451	6	18	165	150	23	11781
SEP-2014	6713	1450	2	25	168	158	31	11820
OCT-2014	6738	1438	7	21	159	146	25	11847
NOV-2014	6732	1451	12	19	135	144	-6	11871
DEC-2014	6744	1473	7	39	136	150	12	11920
JAN-2015	6710	1511	13	24	149	187	-34	11955
FEB-2015	6761	1494	7	36	187	162	51	12007
MAR-2015	6812	1468	7	29	174	143	51	12047
APR-2015	6812	1473	15	28	169	172	0	12083
MAY-2015	6853	1455	9	33	171	148	41	12124
JUN-2015	6877	1471	5	36	155	160	24	12171
JUL-2015	6913	1464	5	25	165	147	36	12209
AUG-2015	6913	1475	7	20	145	157	0	12240
SEP-2015	6916	1495	9	33	157	176	3	12282
OCT-2015	6946	1477	15	25	170	146	30	12319
NOV-2015	7002	1450	9	29	184	147	56	12360
DEC-2015	6981	1490	10	22	146	178	-21	12392

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	6557	0.72%	91.89%	6.31%	1.08%	100.00%
FEB-2014	50	6034	418	68	6570	0.76%	91.84%	6.36%	1.04%	100.00%
MAR-2014	50	6054	424	70	6598	0.76%	91.76%	6.43%	1.06%	100.00%
APR-2014	46	6067	422	76	6611	0.70%	91.77%	6.38%	1.15%	100.00%
MAY-2014	47	6138	418	74	6677	0.70%	91.93%	6.26%	1.11%	100.00%
JUN-2014	50	6107	416	71	6644	0.75%	91.92%	6.26%	1.07%	100.00%
JUL-2014	47	6147	415	73	6682	0.70%	91.99%	6.21%	1.09%	100.00%
AUG-2014	47	6170	414	72	6703	0.70%	92.05%	6.18%	1.07%	100.00%
SEP-2014	50	6185	424	71	6730	0.74%	91.90%	6.30%	1.05%	100.00%
OCT-2014	47	6206	434	73	6760	0.70%	91.80%	6.42%	1.08%	100.00%
NOV-2014	50	6214	424	70	6758	0.74%	91.95%	6.27%	1.04%	100.00%
DEC-2014	45	6229	421	74	6769	0.66%	92.02%	6.22%	1.09%	100.00%
JAN-2015	47	6182	440	74	6743	0.70%	91.68%	6.53%	1.10%	100.00%
FEB-2015	47	6221	451	73	6792	0.69%	91.59%	6.64%	1.07%	100.00%
MAR-2015	47	6287	436	67	6837	0.69%	91.96%	6.38%	0.98%	100.00%
APR-2015	46	6302	435	67	6850	0.67%	92.00%	6.35%	0.98%	100.00%
MAY-2015	47	6344	431	68	6890	0.68%	92.08%	6.26%	0.99%	100.00%
JUN-2015	49	6338	447	72	6906	0.71%	91.78%	6.47%	1.04%	100.00%
JUL-2015	46	6365	454	67	6932	0.66%	91.82%	6.55%	0.97%	100.00%
AUG-2015	48	6366	446	70	6930	0.69%	91.86%	6.44%	1.01%	100.00%
SEP-2015	47	6384	441	64	6936	0.68%	92.04%	6.36%	0.92%	100.00%
OCT-2015	49	6414	443	64	6970	0.70%	92.02%	6.36%	0.92%	100.00%
NOV-2015	52	6461	445	67	7025	0.74%	91.97%	6.33%	0.95%	100.00%
DEC-2015	51	6440	450	62	7003	0.73%	91.96%	6.43%	0.89%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2381 37%	7 17%	1994 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3862 61%	36 86%	4269 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3880 61%	37 84%	4286 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2430 38%	9 24%	2062 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	29 76%	3905 61%	29 76%	4293 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3918 60%	32 73%	4298 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3912 60%	24 77%	4286 66%
SEP-2014	15 38%	2517 39%	12 31%	2146 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3905 60%	24 62%	4285 66%
OCT-2014	10 37%	2545 39%	9 33%	2173 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3905 60%	17 63%	4286 65%
NOV-2014	6 25%	2547 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3895 59%	19 79%	4268 65%
DEC-2014	13 27%	2576 39%	9 18%	2205 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3873 59%	37 76%	4245 65%
JAN-2015	10 29%	2584 40%	10 29%	2221 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3848 59%	25 71%	4212 64%
FEB-2015	8 15%	2593 39%	8 15%	2228 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3883 59%	44 85%	4246 64%
MAR-2015	10 25%	2610 39%	10 25%	2253 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3916 59%	30 75%	4272 64%
APR-2015	10 29%	2626 40%	10 29%	2267 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3917 59%	24 69%	4273 64%
MAY-2015	8 20%	2640 40%	7 18%	2282 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3931 59%	33 83%	4285 64%
JUN-2015	10 21%	2636 39%	10 21%	2290 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3949 59%	37 79%	4300 64%
JUL-2015	4 11%	2660 40%	4 11%	2314 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3951 59%	34 89%	4301 64%
AUG-2015	13 42%	2678 40%	12 39%	2337 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 58%	3946 59%	18 58%	4286 64%
SEP-2015	17 40%	2720 40%	15 36%	2377 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	25 60%	3920 58%	25 60%	4261 63%
OCT-2015	11 30%	2753 41%	10 27%	2409 36%	0 0%	103 2%	0 0%	13 0%	0 0%	8 0%	26 70%	3913 58%	27 73%	4252 63%
NOV-2015	17 41%	2796 41%	15 37%	2451 36%	1 2%	102 1%	0 0%	13 0%	0 0%	8 0%	24 59%	3920 58%	25 61%	4252 63%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2015	5 16%	2802 41%	5 16%	2463 36%	0 0%	95 1%	0 0%	12 0%	0 0%	8 0%	27 84%	3893 57%	27 84%	4218 62%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	738 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	761 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2139 62%	6 46%	868 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2132 62%	5 50%	889 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2106 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2074 61%	12 55%	922 27%	3 14%	385 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2030 60%	6 50%	932 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2031 60%	18 69%	960 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2044 60%	8 47%	971 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%
APR-2015	0 0%	12 0%	7 33%	2026 60%	14 67%	990 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2003 59%	6 38%	1020 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1970 58%	10 56%	1037 31%	0 0%	359 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1962 58%	11 79%	1051 31%	1 7%	352 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1948 58%	7 64%	1057 31%	3 27%	346 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 25%	1917 57%	11 69%	1064 32%	1 6%	339 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
OCT-2015	0 0%	10 0%	5 31%	1905 57%	10 63%	1091 33%	1 6%	332 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
NOV-2015	0 0%	10 0%	5 31%	1887 56%	9 56%	1110 33%	2 13%	329 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%
OCT-2015	0	0%	1	0%
NOV-2015	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2015	0 0%	11 0%	3 25%	1848 56%	8 67%	1119 34%	1 8%	328 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
DEC-2015	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	Efavirenz		Etravirine		Nevirapine		Rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 50%	1280 46%	1 13%	303 11%	1 13%	926 34%	2 25%	258 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	257 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1231 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1207 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1189 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	900 34%	2 25%	254 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	892 34%	4 50%	251 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	889 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1097 43%	1 11%	305 12%	0 0%	874 35%	0 0%	256 10%
OCT-2015	2 50%	1086 43%	0 0%	312 12%	1 25%	867 34%	1 25%	251 10%
NOV-2015	4 67%	1076 43%	0 0%	312 12%	0 0%	865 35%	2 33%	254 10%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.8 Number of Participants on Non-Nucleosides by INGREDIENT (continued)

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2015	3 100%	1060 43%	0 0%	312 13%	0 0%	862 35%	0 0%	255 10%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	76 5%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	252 17%	0 0%	74 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	267 18%	0 0%	74 5%	2 18%	919 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	281 18%	0 0%	73 5%	4 27%	919 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	309 19%	0 0%	71 4%	2 13%	906 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 29%	6 35%	335 19%	0 0%	72 4%	0 0%	888 51%	0 0%	1 0%
JAN-2015	13 72%	541 30%	4 22%	349 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	577 31%	8 33%	355 19%	0 0%	74 4%	2 8%	880 48%	0 0%	1 0%
MAR-2015	9 50%	600 32%	5 28%	367 20%	0 0%	69 4%	4 22%	869 47%	0 0%	2 0%
APR-2015	7 50%	628 33%	4 29%	373 20%	2 14%	67 4%	1 7%	862 45%	0 0%	2 0%
MAY-2015	11 65%	665 34%	4 24%	382 20%	1 6%	70 4%	2 12%	864 44%	0 0%	2 0%
JUN-2015	15 56%	712 35%	8 30%	396 20%	0 0%	72 4%	4 15%	875 43%	0 0%	1 0%
JUL-2015	11 58%	748 37%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	12 71%	785 38%	4 24%	413 20%	0 0%	70 3%	1 6%	855 41%	0 0%	1 0%
SEP-2015	17 81%	850 40%	2 10%	414 19%	0 0%	65 3%	2 10%	857 40%	0 0%	1 0%
OCT-2015	14 70%	890 40%	6 30%	437 20%	0 0%	65 3%	0 0%	852 39%	0 0%	1 0%
NOV-2015	15 71%	940 42%	6 29%	440 19%	0 0%	67 3%	0 0%	854 38%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT (continued)

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2015	11 52%	992 43%	9 43%	445 19%	0 0%	66 3%	1 5%	842 37%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.66	2246	33.80	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.31	2235	33.45	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.30	890	13.28	186	2.77	72	1.07	858	12.80
SEP-2014	2437	36.21	2221	33.00	946	14.06	187	2.78	71	1.05	868	12.90
OCT-2014	2417	35.75	2190	32.40	1008	14.91	192	2.84	73	1.08	880	13.02
NOV-2014	2419	35.79	2159	31.95	1056	15.63	184	2.72	70	1.04	870	12.87
DEC-2014	2398	35.43	2144	31.67	1103	16.29	185	2.73	74	1.09	865	12.78
JAN-2015	2348	34.82	2124	31.50	1137	16.86	179	2.65	74	1.10	881	13.07
FEB-2015	2364	34.81	2111	31.08	1176	17.31	178	2.62	73	1.07	890	13.10
MAR-2015	2398	35.07	2112	30.89	1203	17.60	184	2.69	67	0.98	873	12.77
APR-2015	2392	34.92	2095	30.58	1239	18.09	184	2.69	67	0.98	873	12.74
MAY-2015	2399	34.82	2094	30.39	1277	18.53	179	2.60	68	0.99	873	12.67
JUN-2015	2369	34.30	2078	30.09	1324	19.17	172	2.49	72	1.04	891	12.90
JUL-2015	2375	34.26	2068	29.83	1353	19.52	171	2.47	67	0.97	898	12.95
AUG-2015	2369	34.18	2044	29.49	1384	19.97	168	2.42	70	1.01	895	12.91
SEP-2015	2330	33.59	2033	29.31	1450	20.91	168	2.42	64	0.92	891	12.85
OCT-2015	2335	33.50	2007	28.79	1494	21.43	167	2.40	64	0.92	903	12.96
NOV-2015	2333	33.21	2014	28.67	1542	21.95	160	2.28	67	0.95	909	12.94
DEC-2015	2298	32.81	1984	28.33	1583	22.60	161	2.30	62	0.89	915	13.07

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	24	3	1	6	6	7	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	19	5	1	0	4	8	475
DEC-2014	39	3	5	7	11	13	401
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	20	2	3	4	2	8	460
SEP-2015	33	7	1	5	3	15	500
OCT-2015	25	5	2	3	4	9	430
NOV-2015	29	5	1	5	6	10	400
DEC-2015	22	2	3	4	4	8	370

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10027	2578
FEB-2014	10049	2571
MAR-2014	10062	2557
APR-2014	10092	2560
MAY-2014	10116	2554
JUN-2014	10151	2564
JUL-2014	10163	2552
AUG-2014	10212	2586
SEP-2014	10254	2596
OCT-2014	10276	2604
NOV-2014	10307	2626
DEC-2014	10348	2630
JAN-2015	10390	2660
FEB-2015	10436	2667
MAR-2015	10475	2676
APR-2015	10495	2688
MAY-2015	10549	2712
JUN-2015	10635	2759
JUL-2015	10704	2807
AUG-2015	10770	2862
SEP-2015	10855	2916
OCT-2015	10906	2956
NOV-2015	10969	2996
DEC-2015	11019	3026

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
December 2015

N = 7003

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2015

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2015

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	12	14	8
	50+	21	31	15
	Total HSDA:	33	45	23
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	4	4	3
	35-49	18	24	11
	50+	46	61	35
	Total HSDA:	69	90	50
OKANAGAN	0-19	4	4	3
	20-34	22	23	18
	35-49	95	109	69
	50+	196	284	159
	Total HSDA:	317	420	249
THOMPSON/CARIBOO/ SHUSWAP	0-19	5	5	0
	20-34	22	22	17
	35-49	57	69	47
	50+	89	131	77
	Total HSDA:	173	227	141
Total HA:		592	782	463

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	4
	20-34	48	49	38
	35-49	182	216	135
	50+	352	507	286
Total HA:		592	782	463

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	458	619	368
Female	134	163	95

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	463	53	570	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	7	5
	<5 years	10	8
	Total HSDA:	33	23
KOOTENAY BOUNDARY	10 years or more	33	22
	5 years or more	21	17
	<5 years	15	11
	Total HSDA:	69	50
OKANAGAN	10 years or more	168	122
	5 years or more	73	61
	<5 years	76	66
	Total HSDA:	317	249
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	86	60
	5 years or more	33	32
	<5 years	54	49
	Total HSDA:	173	141
Total HA:		592	463

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	303	214
	5 years or more	134	115
	<5 years	155	134
Total HA:		592	463

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	35	50	13	23
KOOTENAY BOUNDARY	62	110	27	43
OKANAGAN	192	660	66	238
THOMPSON/CARIBOO/SHUSWAP	124	409	46	108
Total:	413	1229	152	412

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	1
KOOTENAY BOUNDARY	12
OKANAGAN	43
THOMPSON/CARIBOO/SHUSWAP	38
Total:	94

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
FRASER Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	26	27	20
	35-49	115	126	86
	50+	166	226	133
	Total HSDA:	314	386	244
FRASER NORTH	0-19	18	18	4
	20-34	114	115	94
	35-49	358	408	259
	50+	452	705	368
	Total HSDA:	942	1246	725
FRASER SOUTH	0-19	11	11	5
	20-34	97	99	71
	35-49	362	411	294
	50+	411	610	339
	Unknown	0	1	0
	Total HSDA:	881	1132	709
Total HA:		2137	2764	1678

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	36	36	14
	20-34	237	241	185
	35-49	835	945	639
	50+	1029	1541	840
	Unknown	0	1	0
Total HA:		2137	2764	1678

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1618	2122	1304
Female	519	642	374

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1678	50	600	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	143	108
	5 years or more	89	71
	<5 years	82	65
	Total HSDA:	314	244
FRASER NORTH	10 years or more	456	332
	5 years or more	233	183
	<5 years	253	210
	Total HSDA:	942	725
FRASER SOUTH	10 years or more	395	304
	5 years or more	242	203
	<5 years	244	202
	Total HSDA:	881	709
Total HA:		2137	1678

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	994	744
	5 years or more	564	457
	<5 years	579	477
Total HA:		2137	1678

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	126	398	46	82
FRASER NORTH	226	1387	64	282
FRASER SOUTH	202	1162	48	333
Total:	554	2947	158	697

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	178
FRASER NORTH	620
FRASER SOUTH	494
Total:	1292

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	20	20	19
	35-49	87	101	72
	50+	193	313	171
	Total HSDA:	302	436	262
RICHMOND	0-19	5	5	1
	20-34	22	22	18
	35-49	46	49	40
	50+	75	114	61
	Total HSDA:	148	190	120
VANCOUVER	0-19	56	59	7
	20-34	408	416	322
	35-49	1596	1866	1194
	50+	2385	3964	1896
	Total HSDA:	4445	6305	3419
Total HA:		4895	6931	3801

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	63	66	8
	20-34	450	458	359
	35-49	1729	2016	1306
	50+	2653	4391	2128
Total HA:		4895	6931	3801

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4302	6093	3354
Female	591	836	447

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3801	51	600	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	169	140
	5 years or more	51	47
	<5 years	82	75
	Total HSDA:	302	262
RICHMOND	10 years or more	69	52
	5 years or more	37	30
	<5 years	42	38
	Total HSDA:	148	120
VANCOUVER	10 years or more	2222	1596
	5 years or more	1102	874
	<5 years	1121	949
	Never on ART	0	0
	Total HSDA:	4445	3419
Total HA:	4895	3801	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2460	1788
	5 years or more	1190	951
	<5 years	1245	1062
	Never on ART	0	0
Total HA:		4895	3801

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	140	365	55	94
RICHMOND	41	257	13	88
VANCOUVER	529	9764	207	5245
Total:	710	10386	275	5427

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	6
RICHMOND	1
VANCOUVER	97
Total:	104

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	22	24	18
	35-49	82	95	65
	50+	160	254	132
	Total HSDA:		266	375
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	13	14	11
	35-49	35	39	29
	50+	58	87	50
	Total HSDA:		108	142
SOUTH VANCOUVER ISLAND	0-19	9	9	2
	20-34	42	44	31
	35-49	217	255	174
	50+	378	592	297
	Total HSDA:		646	900
Total HA:		1020	1417	811

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	4
	20-34	77	82	60
	35-49	334	389	268
	50+	596	933	479
Total HA:		1020	1417	811

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	820	1144	656
Female	200	273	155

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	811	52	470	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	128	100
	5 years or more	67	55
	<5 years	71	61
	Total HSDA:	266	216
NORTH VANCOUVER ISLAND	10 years or more	47	38
	5 years or more	26	23
	<5 years	35	30
	Total HSDA:	108	91
SOUTH VANCOUVER ISLAND	10 years or more	316	221
	5 years or more	167	138
	<5 years	163	145
	Total HSDA:	646	504
Total HA:		1020	811

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	491	359
5 years or more	260	216
<5 years	269	236
Total HA:	1020	811

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	167	706	80	181
NORTH VANCOUVER ISLAND	115	234	49	72
SOUTH VANCOUVER ISLAND	182	1519	46	530
Total:	464	2459	175	783

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	43
NORTH VANCOUVER ISLAND	31
SOUTH VANCOUVER ISLAND	86
Total:	160

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	4	5	1
	35-49	16	18	12
	50+	19	24	12
	Total HSDA:	40	48	25
NORTH WEST	0-19	1	1	0
	20-34	9	13	8
	35-49	25	37	19
	50+	30	45	22
	Total HSDA:	65	96	49
NORTHERN INTERIOR	0-19	5	5	4
	20-34	27	30	16
	35-49	68	85	53
	50+	75	121	61
	Total HSDA:	175	241	134
Total HA:		280	385	208

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	4
	20-34	40	48	25
	35-49	109	140	84
	50+	124	190	95
Total HA:		280	385	208

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	174	243	132
Female	106	142	76

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	208	48	490	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	15	8
	5 years or more	13	8
	<5 years	12	9
	Total HSDA:	40	25
NORTH WEST	10 years or more	17	7
	5 years or more	27	23
	<5 years	21	19
	Total HSDA:	65	49
NORTHERN INTERIOR	10 years or more	53	34
	5 years or more	50	43
	<5 years	72	57
	Total HSDA:	175	134
Total HA:		280	208

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	85	49
	5 years or more	90	74
	<5 years	105	85
Total HA:		280	208

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	31	58	8	11
NORTH WEST	62	140	20	24
NORTHERN INTERIOR	97	385	24	182
Total:	190	583	52	217

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	17
NORTHERN INTERIOR	22
Total:	45

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	10	6
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	17	30	9
	THOMPSON/CARIBOO/SHUSWAP	19	35	17
	Total HA:	46	81	35
FRASER	FRASER EAST	31	39	23
	FRASER NORTH	58	87	42
	FRASER SOUTH	68	94	55
	Total HA:	157	220	120
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	22	41	19
	RICHMOND	7	12	6
	VANCOUVER	502	781	421
	Total HA:	531	834	446
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	47	72	36
	NORTH VANCOUVER ISLAND	13	22	12
	SOUTH VANCOUVER ISLAND	34	71	28
	Total HA:	94	165	76
NORTHERN	NORTH EAST	11	13	7
	NORTH WEST	32	55	27
	NORTHERN INTERIOR	61	93	53
	Total HA:	104	161	87
Total:		932	1461	764

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	588	938	470
Female	344	523	294

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	764	49	470	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Combination Therapy: using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.





Dolutegravir (DTG): an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

Efavirenz (Sustiva, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

Emtricitabine (FTC): a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

Famciclovir (Famvir): a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (MVC, Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.





Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).





PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a pill that contains DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

Tenofovir (Viread, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare's trade name for a pill that contains DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare's trade name for a pill that contains ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a pill that contains TENOFOVIR and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

